Causes of Death and Influencing Factors in Patients with Atrial Fibrillation
- PMID: 27476087
- DOI: 10.1016/j.amjmed.2016.06.045
Causes of Death and Influencing Factors in Patients with Atrial Fibrillation
Abstract
Background: Atrial fibrillation is associated with a higher mortality, but causes of death of atrial fibrillation patients and their specific predictors have been less well defined. We aimed to identify the causes of death among atrial fibrillation patients and secondly, clinical predictors for the different modes of deaths.
Methods: Patients diagnosed with atrial fibrillation in a four-hospital institution between 2000 and 2010 were identified. During a follow-up of 929 ± 1082 days (median 456, interquartile 10-1584), 1253 deaths were recorded (yearly rate 5.5%).
Results: Cardiovascular deaths accounted for 54% and noncardiovascular for 43%. The three main causes of death were heart failure (29%), infection (18%), and cancer (12%). Fatal stroke or fatal bleeding each accounted for 7% of all deaths. On multivariate analysis, the strongest predictors of death were permanent atrial fibrillation, heart failure (whether with decreased or with preserved ejection fraction), previous bleeding, and renal failure, which were independently associated with an increase in the risk of all-cause mortality (35%, 78%, 42%, and 79%, respectively), cardiovascular mortality (43%, 129%, 46%, and 93%, respectively), and noncardiovascular mortality (21%, 45%, 40%, and 50%, respectively). Oral anticoagulant use was independently associated with a lower risk of all-cause mortality (hazard ratio [HR] 0.62; 95% confidence interval [CI], 0.54-0.71; P <.0001), cardiovascular mortality (HR 0.60; 95% CI, 0.49-0.72; P <.0001), and noncardiovascular mortality (HR 0.60; 95% CI, 0.49-0.74; P <.0001).
Conclusions: The majority of deaths were related to a cardiovascular origin, and heart failure was the most common cause of death in atrial fibrillation patients. Despite the high risk of stroke associated with atrial fibrillation, only 7% died from stroke. Optimization of management of any underlying heart disease and associated comorbidities should be a relevant therapeutic target to reduce total mortality in atrial fibrillation patients.
Keywords: Atrial fibrillation; Death; Heart failure; Oral anticoagulation; Stroke.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.Circ Arrhythm Electrophysiol. 2012 Apr;5(2):312-8. doi: 10.1161/CIRCEP.111.967000. Epub 2012 Feb 7. Circ Arrhythm Electrophysiol. 2012. PMID: 22319005
-
Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation.Circulation. 2018 Oct 16;138(16):1666-1676. doi: 10.1161/CIRCULATIONAHA.118.034125. Circulation. 2018. PMID: 29871978 Clinical Trial.
-
Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project.Am J Med. 2014 Oct;127(10):972-8. doi: 10.1016/j.amjmed.2014.05.035. Epub 2014 Jun 12. Am J Med. 2014. PMID: 24929021
-
Causes of death in atrial fibrillation: Challenges and opportunities.Trends Cardiovasc Med. 2017 Oct;27(7):494-503. doi: 10.1016/j.tcm.2017.05.002. Epub 2017 May 10. Trends Cardiovasc Med. 2017. PMID: 28602539 Review.
-
Impact of atrial fibrillation on mortality in patients with chronic heart failure.Eur J Heart Fail. 2002 Oct;4(5):571-5. doi: 10.1016/s1388-9842(02)00094-6. Eur J Heart Fail. 2002. PMID: 12413498 Review.
Cited by
-
Prognostic Impact of Severe Atrial Functional Tricuspid Regurgitation in Atrial Fibrillation Patients.J Clin Med. 2022 Dec 1;11(23):7145. doi: 10.3390/jcm11237145. J Clin Med. 2022. PMID: 36498719 Free PMC article.
-
Levosimendan and Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.Arq Bras Cardiol. 2024 Jul;121(7):e20230856. doi: 10.36660/abc.20230856. Arq Bras Cardiol. 2024. PMID: 39166566 Free PMC article. English, Portuguese.
-
Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany - A retrospective cohort study.Int J Cardiol Heart Vasc. 2019 May 9;23:100367. doi: 10.1016/j.ijcha.2019.100367. eCollection 2019 Jun. Int J Cardiol Heart Vasc. 2019. PMID: 31111087 Free PMC article.
-
Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project.J Gen Intern Med. 2018 Jun;33(6):847-854. doi: 10.1007/s11606-017-4279-4. Epub 2018 Mar 22. J Gen Intern Med. 2018. PMID: 29569024 Free PMC article.
-
Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort.Eur J Intern Med. 2020 Dec;82:105-111. doi: 10.1016/j.ejim.2020.09.024. Epub 2020 Oct 13. Eur J Intern Med. 2020. PMID: 33067121 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical